Présentation de l'entreprise

“In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solution (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®) consisting of different chemical families (lipids, polymers).

Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents.

The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus) , therapeutic cancer models (melanoma, liver, breast and cervical cancers) and therapeutic models (muscular dystrophy, anemia in kidney failure)

In-Cell-Art has recently advanced vaccines into regulatory preclinical studies for human clinical trials and shown promising safety and immunogenicity profiles.” from incellart.com